Dear Sirs! Let me introduce you to the company GENIS, created in the 90s of the last century by a group of scientists, doctors and professional managers with the aim of promoting advanced medical technologies to the market of Ukraine and other countries.

Modern medical technologies are the most promising sector in Ukrainian healthcare. The quality of treatment achieved by traditional medicine no longer satisfies the demands of demanding patients.

Cell therapy is the most modern direction in medicine of the 21st century. It provides effective treatment of many diseases using stem cells and tissues, as well as biologically active substances secreted by them.

Stem cells (SC) are characterized by an unusually high activity in providing hematopoiesis.

Thus, SC transplantation leads to an increase in the number of leukocytes in cancer patients with chemoradiation depression of hematopoiesis from 2 to 5×10⁹/l in two weeks.

The introduction of SC into an adult organism and their engraftment among aging and pathologically altered cells creates a unique situation when the cells and organs of an adult organism are constantly affected by the most powerful factors of development, renewal and provision of functions, which are present and act only in the embryonic period of development. Due to this, SC:

— normalize and stimulate metabolism;
— normalize the activity of the immune and neuroendocrine systems;
— have a pronounced antitumor effect;
— have a pronounced therapeutic effect in a wide variety of pathologies;
— rejuvenate the body, preventing premature aging

In accordance with the above, SCs are recommended for the treatment of:

— primary (congenital) immunodeficiencies;
— secondary environmental immunodeficiencies with neuroendocrine, infectious, allergic and autoimmune syndromes; and

• diabetes
• oncopathologies
• cardiovascular diseases
• brain diseases
• ophthalmology
• A number of diseases require organ transplantation, which is difficult to do for a number of reasons, and therefore there are many tens of thousands of patients on waiting lists who do not always wait to receive new organs.
• All these problems can be successfully solved with the help of cellular technologies that have been developed in recent years.
• In addition, SC is the only drug containing hematopoietic cells that produce various compounds similar to erythropoietin and colony-stimulating factors, as well as other biologically active substances that have, among other things, antitumor activity. For example, α-fetoprotein is responsible for powerful stimulation and renewal of many vital functions of the human body.
• The attractiveness of this type of treatment is that there are no analogues in terms of versatility and quality of impact on the human body to cellular preparations. In addition, the entire technological chain from the production of SC, storage and treatment of patients has been developed